Generics 22

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Imatinib mesylate manufacturers

22 products found

Filters

Filters

Filters , active

Country of origin : India

Clear all

22 products found

imatinib mesylate

Capsules 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19783

Manufacturer usually replies in 2 days

imatinib mesylate

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18530

Manufacturer usually replies in 4 days

imatinib mesylate

Tablets 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Registered in
India
Available for
Licensing with supply, Distribution only, Technology transfer
Manufacturer #19588

Manufacturer usually replies in 7 days

imatinib mesylate

Tablets 30 Tablet's Pack

Dossier type
CTD
Dossier status
Country of origin
India
GMP approvals
WHO
Manufacturer #12319

Manufacturer usually replies in 5 days

imatinib mesylate

Capsules 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20087

Manufacturer usually replies in 8 days

imatinib mesylate

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19670

Manufacturer usually replies in 8 days

imatinib mesylate

Tablets 100 mg, 400 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA
Manufacturer #17753

Manufacturer usually replies in 10 days

imatinib mesylate

Capsules 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20801

Manufacturer usually replies in 11 days

imatinib mesylate

Tablets 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
Canada, WHO
Manufacturer #17753

Manufacturer usually replies in 10 days

imatinib mesylate

Capsules 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17753

Manufacturer usually replies in 10 days

imatinib mesylate

Capsules 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
India
Manufacturer #20740

Manufacturer usually replies in 19 days

imatinib mesylate

Capsules 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20511

Manufacturer usually replies in 21 days

imatinib mesylate

Injection 500 mg, 1000 mg, 2000 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19912

Manufacturer usually replies in 18 days

imatinib mesylate

Tablets for oral solution 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19912

Manufacturer usually replies in 18 days

imatinib mesylate

Tablets 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17392

Manufacturer usually replies in 18 days

imatinib mesylate

Tablets 100mg, 400mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #16177

Manufacturer usually replies in 14 days

imatinib mesylate

Tablets 100/400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO, INVIMA
Manufacturer #10726

Manufacturer usually replies in 7 days

imatinib mesylate

Tablets 400mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Available for
Licensing with supply
Manufacturer #10323

Manufacturer usually replies in 5 days

imatinib mesylate

Capsules 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Available for
Licensing with supply
Manufacturer #10323

Manufacturer usually replies in 5 days

imatinib mesylate

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30830

Want to view all 22 products? Create your free account today!

Imatinib Mesylate

Imatinib Mesylate is used to treat certain types of leukaemia, type of cancers that begins in the white blood cells, other cancers and disorders of the blood cells. Imatinib is also used to treat certain types of gastrointestinal stromal tumours, a type of tumour that grows in the walls of the digestive passages and may spread to other parts of the body. Imatinib is also used to treat tumours that forms under the top layer of skin, especially when the tumour cannot be removed surgically, has spread to other parts of the body, or has come back after surgery. Imatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Imatinib is sold under the brand name Gleevec among others.
Scientists at Ciba-Geigy (which merged with Sandoz in 1996 to become Novartis) invented Imatinib in the late 1990s, in a team led by biochemist Nicholas Lydon and that included Elisabeth Buchdunger and Jürg Zimmermann.

Forms and Dosage

It is sold in the tablet form in 100mg, 400mg strengths, in the treatment of Acute Lymphoblastic Leukaemia, the Indicated dosage for adults is 600 mg per day. In the treatment of Myelodysplastic/Myeloproliferative Diseases, the standard adult dose is 400 mg. in the treatment of Chronic Eosinophilic Leukemia, 100 mg which may increase to 400 mg. for treating Mastocytosis, the Indicated dosage for adults with aggressive systemic mastocytosis is 400 mg PO qDay and for Gastrointestinal Stromal Tumors, 400 mg

The cost of Imatinib Mesylate

The wholesale cost in the developing world is about US$1,386.49–19,162.50 a year. Whereas In the United States a typical dose for a year has a wholesale cost of $84,408, while in the United Kingdom the NHS was paying about £20,980 ($27,973) in 2016. Prices for a 100 mg pill of Gleevec internationally range from $20 to $30, although generic Imatinib is cheaper, as low as $2 per pill.

How does Imatinib Mesylatework?

Imatinib is a cancer growth blocker called a tyrosine kinase inhibitor. These inhibitors are proteins that cells use to signal to each other to grow. There are a number of different tyrosine kinases and blocking them stops the cancer cells growing. Imatinib targets different tyrosine kinases, depending on the type of cancer.

Finding Imatinib Manufacturers and Suppliers

The process of finding trusted Imatinib manufacturers and Imatinib suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of Imatinib . The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.